Abstract: The administration of several intravenous products on the same catheter is a very common situation in neonatology, where the stakes are high and the dangers sometimes unknown to clinicians. A large number of factors are involved in this administration, directly related to the installation of the infusion line. Moreover, the therapeutics used are often limited, and excluding classic "Marketing Authorization". Some of these products may prove to be incompatible and thus lose their effectiveness, or even generate particles that are likely to be administered to the patient. We must be aware of these risks in order to optimize the prescription and administration of these intravenous products, especially as we treat fragile and immature patients. The aim of this work is to review the literature on the subject for the prescribers of neonatology units.
Introduction Population
The population of Neonatal Intensive Care Units (NICUs) includes both very immature patients (24 weeks of gestation and 500 g) and often carrying complex pathologies (medical and/or surgical). These children are technically demanding, and the administration of intravenous (IV) therapies is constant.
There are few drugs with a Neonatal Marketing Authorization, so prescriptions are based on recommendations and must be adapted to the gestational age and weight of the newborns [1] .
In addition to the medicines to be administered (antibiotics, sedatives, amines, etc.), these patients very often require parenteral (binary or ternary) nutrition (PN), and most of this is done via a single mono-lumen central venous catheter.
All of these therapies result in infusion volumes that can be significant, sometimes with "hidden" intakes such as sodium, and therefore need to be accounted for in total daily intakes.
Since the blood mass is estimated at 80 ml/kg, it is necessary in these low-weight patients to reason in minimum volumes to be infused, while respecting the concentration limits for each drug, as this may lead to water overload.
The hepatic or renal elimination of these drugs is also different in view of their immaturity, and the doses must therefore be appropriate [2, 3] . For example, vancomycin now has a formula for calculating the necessary dose for 24 hours according to the creatinine concentration of the child, which avoids overdosage and therefore nephrotoxicity [4, 5] .
Continuous or discontinuous injectable drugs are administered at low volumes and flow rates on the same infusion line as parenteral nutrition (which also often has a low flow rate). This is likely to cause disturbances in administration, and in particular interactions during prolonged contact in the tubing.
In addition, preterm infants are placed in incubators to maintain optimum thermal and hygrometric conditions: an ambient temperature of 35-36°C and a humidity of up to 80 %. The perfusion line, placed partly inside the incubator, is therefore subjected to these same environmental conditions.
Similarly, during the first week of life, newborns may need phototherapy, which can alter certain photo-sensitive medicines, including vitamins [6] . Moreover, light can create reactive oxygen species that can oxide other chemicals.
Factors
Several factors are involved in the administration of IV treatments, in particular in relation to the devices used.
One consequence is the existence of significant variability in the volumes delivered to the patient.
Thus, in premature babies < 1 000 g, it was shown that only 70 % of the expected dose was delivered 75 min after the start of the drug infusion [7] . This is therefore problematic for certain drugs such as catecholamines, aminoglycosides or even insulin.
Studies have shown haemodynamic and oxygenation changes of newborns during the administration of dopamine or noradrenaline [8, 9] .
When intravenous treatment is administered, there are 7 factors that can influence this administration: 1. The height separating the end of the catheter from the syringe pump delivering the drug. A vertical movement of the syringe pump delivering the drug solution to the patient will result in a bolus (after an upward displacement), a sudden fluid retraction (after a downward movement) and a no-flow time (ranging from a few seconds to several minutes). These changes are affected by the height of the movement, the type and volume of the syringe, the type and length of the tubing, the pressure exerted or the programmed infusion rate. It has been demonstrated that there was no correlation between the infusion flow and the no-flow time, and that the delivery rate was inversely proportional to the set infusion rate during vertical movements of the pump [10, 11] . 2. Characteristics of the syringe delivering the drug.
The volume and design of the syringe affect the volumes delivered to the patient, altering the time to reach the steady state of the drug delivery rate, the triggering time of the ratchet occlusion alarm, but also on the time without flow, the suction volume and the volume of the bolus following a vertical movement of the syringe pump [12, 13, 14, 15] . The impact of this factor is amplified with the programming of low flows. 3. Characteristics of the tubing delivering the drug.
The compliance of the drug delivery tubing affects the variability of its infusion rate, affecting the time to initiate the occlusion alarm, time without flow, suction volume, and bolus volume during vertical movements of the syringe pump [16, 17] . The impact of this factor is further enhanced in combination with high volume syringes (50 mL) and low flow programming. 4. The use of non-return and anti-siphon valves.
Non-return valves and anti-siphon valves are unidirectional valves, that is, they allow the passage of the solution only in one direction, either to the patient. They are referred to as non-return valves because they prevent the fluid from rising to the other infusion lines. Anti-siphon valves are referred to as they prevent a free flow of the contents of the syringe by gravity, resulting from the presence of air in the syringe. They are characterized by a high opening pressure (100-150 mmHg), which is responsible for lengthening the infusion start-up time for low flows and a no-flow time after a lowering of the syringe pump [18, 19] . 5. The use of in-line filters.
The in-line filters are inserted into the infusion sets to prevent deleterious administration of particles to the patient. These particles can come directly from the preparation (glass or rubber fragments) or be linked to the existence of drug incompatibilities in the context of a multi-infusion [20] . The administration of these particles can have serious consequences for the patient, as endothelial lesions and thrombosis [21, 22] , and the use of inline filters has been shown to reduce the number of general complications and Systemic Inflammatory Response Syndrome (SIRS) [23] . However, a recent meta-analysis did not reveal a significant effect of online filters on overall mortality in pediatrics/neonatology [24] . Not all drugs are filterable, such as suspensions, micellar solutions, liposomes, having a high viscosity or a risk of adsorption on the filter membrane. In addition, a recent study showed that the presence of an in-line filter on the infusion line reduced flow irregularities, as well as the start-up time of the syringe pumps at low flow rates [25] .
6. The use of multi-access devices.
As several medications (including PN and IV lipids) are administered simultaneously, the infusion line set comports multi-access devices. Thus, stopcocks or octopusses are often added to the infusion line. The factors affecting the mass flow of medications administered to the patient are: -the internal volume, compliance and design of the multi-access device, -the sum of the infusion rates (also called total flow rate), including the flow rate of the drug and that of the carrier fluid (usually PN), -the conditions for mixing the administered drug integrating the carrier fluid, -the delivery of bolus upstream in the case of stopping, then the resumption of an infusion, -a change in flow during infusion, which is responsible for a delay in returning to steady state, which will be dependent of the flow rate of the carrier fluid as well as on the internal volume of the delivery system. 7. The catheter.
There are several catheters available for NICU patients.
The first vascular access usually used in NICU is the umbilical one, which is a short-term and emergency access. Umbilical venous catheters (UVCs) are commonly used in NICUs to provide intravenous fluids and nutrition, to provide intravenous medications, and for blood sampling. UVCs are used from birth to 5 days of life and are replaced by a Peripherally Inserted Central Catheter (PICC). A PICC is a venous silicon catheter used for a medium or long-term access. The ideal position for the tip of the PICC is in the inferior or superior vena cava. PICC allows drug administration, parenteral nutrition, fluid therapy and infusions. The choice of the catheter will depend on the chosen venous approach, the duration of the infusion, the desired flow rate, the type of drug administered, or the weight of the patient. In addition, there are specific constraints related to the diameter of the catheters and the number of accesses available [26, 27] . The catheter characteristics, in particular the type of material which compose it [28] and the internal volume of the device [29, 30] , have an effect on the volumes delivered to the patient.
These characteristics are amplified with the programming of low infusion rates.
Risks
There are a number of risks associated with prescribing and administering IV treatments, especially in NICU. The first risk is the risk of error [31] .
Errors may occur at every stage between the decision to administer a therapy to the patient and the actual delivery to the patient.
Here are different steps, each of which involves a risk of error: -medical prescription (dose, interval, incompatibilities …) [32] -preparation of the treatment (reconstitution, dilution …) -administration to the patient (patient identity, flow, rinsing, traceability).
Following a finding in our NICU concerning vancomycin administration, we were able to show great disparities during the preparation of this antibiotic and which were related to the use of the needle [33] .
Moreover, it was also demonstrated that the preparation of small volumes was a source of error, and that it was not desirable to inject volumes < 0.3 mL. In this case, a double dilution must be provided in order to obtain sufficient volumes.
Various tools now allow us to limit these risks of errors: prescribing software, drug incompatibilities cross-tables (Figure 1) , absence of transcription of prescriptions, compliance with protocols for preparation, verification at the patient's bed … The second risk is the infectious risk, since these infusion lines are manipulated several times a day, especially during access to multi-access devices, and remain in place for several days to several weeks.
Late onset infections due to the catheter are most often related to coagulase-negative staphylococci, but sometimes the catheter can be colonized with yeast (Candida) [34] . These infections can have serious consequences, and increase the morbidity of NICU patients [35] .
The last risk, sometimes unknown, is that of Systemic Inflammatory Response Syndrome (SIRS).
The SIRS is related to the particle administration during infusion, and has already been well demonstrated for adult patients of intensive care units [22] , and more recently in the pediatric population [36] .
Drug interactions
Incompatibility is an undesirable reaction that occurs between the drug and the solution, container or another drug.
The two types of incompatibilities associated with IV administration are physical and chemical. A drug interaction describes the alteration of a drug effect due to the influence of another substance resulting in a solution that is no longer optimal for the patient after the substances are mixed.
Physical reactions of drugs usually refer to either phase separation or precipitation due to a change of the relation between ionization and nonionization and solubility. The pH-value and the buffer capacity of the IV solutions and the drugs used are major factors responsible for physical interactions.
Repeated blackening of in-line filters had also been observed with particle formation upstream of the device during infusion of binary PN mixtures prepared in bags and delivered in our NICU [37] .
To avoid this, we use a cross-table to check drug incompatibilities before prescribing and/or administering them. Unfortunately, there is still missing datas for several drugs (Figure 1 ).
For example, ceftriaxone is contraindicated in neonates if they require (or are expected to require) treatment with calcium-containing IV solutions, including continuous calcium-containing infusions such as PN because of the risk of precipitation of ceftriaxone-calcium [38] .
Injection or infusion of drugs and fluids releases micro particles into the bloodstream.
Various studies have demonstrated the contamination of infusion solutions with glass particles from opening glass ampoules, particles from rubber stoppers or conglomerates of the PN components. These particles may stimulate the immune system and cause organ damage [39] . Particulate matter are "mobile undissolved particles, other than gas bubbles, unintentionally present in the solutions".
Injectable drug particulate matter are divided into two classes based on the source of the particulate matter: intrinsic particles, defined as those originally associated with the solution, and extrinsic particles, defined as those that enter the container or solution during manufacturing.
Particles may harm the pulmonary endothelium either directly or through activation of complement, platelets and/or neutrophils, leading to the formation of occlusive micro thrombi [40] .
Boehne and al. hypothesis was that infused particles act directly on the microcirculation of several organ systems such as the kidney and lung and induce a systemic hypercoagulability and inflammation [36] .
Their study demonstrate potential beneficial effects of in-line filtration on the preservation of various organ systems, even if further experimental and clinical investigations are necessary to clarify the exact impact of infused particles [36] .
Solutions
Considering all these elements, it seems essential to design the infusion line set with the prescribing habits of the NICU and the needs of the patients.
We also adapt the volume of the syringes according to the perfused flow rates.
We designed our actual infusion line set with NICU nurses and hospital pharmacists.
It was then tested in vitro with solutions of different colors, at the flows prescribed in NICU. This allowed us to highlight the importance of the use of non-return valves because in their absence there was a rise of colored product in the tubings.
The use of in-line filters is now recommended in our NICUs in France and Europe [41, 42] .
We use 2 types of in-line filters: 0.22 µm for PN and filterable drugs and 1.2 µm for IV lipids.
In our NICU the entire line set is changed each 96 hours (and each 24 hours for IV lipids line) (Figure 2) . Some medical devices are also being developed and evaluated for the NICU patients, such as multi-lumen devices, allowing the separation of the different treatments administered in the tubing, which could avoid drug incompatibilities [43] .
Finally, it is also certain that the risk of a prescription error can be limited by the use of a prescription software [44] . We use in our NICU the prescribing software "LOGIPREN ® ", whose drug thesaurus and the dilution and administration protocols have been completely reviewed with the help of referring pharmacists. This software should soon integrate the known drug incompatibilities, and thus further limit the risk of error when prescribing. Figure 2 : Example of an infusion line set used in our NICU for PN, IV lipids, drug infusion and medications with octopuses and autoflushes. There are two parts in the line set: one used for IV lipids which comports a 1.2 µm in-line filter and is removed each 24 hours; and one used for PN, filterable drugs and continuous infusions which comports a 0.22 µm in-line filter and is removed each 96 hours. There is also a special access for non-filterable drugs and/or IV bolus.
Conclusion
The management of prescriptions in NICU patients is a daily and challenging issue.
It requires taking into account the volumes, the devices used and the possible drug incompatibilities in these immature and low weight patients.
The design of the infusion line seems essential and should be carried out in partnership with our pharmacist colleagues, or even tested it in vitro if possible, as we did in our department.
Although this may appear complex, there are now technological solutions adapted to this particular population of NICUs, and new devices are also being developed and tested.
There are still missing data on the various possible drug interactions, but the use of in-line filters may partially limit their consequences.
The real complexity of these administrations in NICUs necessitates close collaboration between neonatologists and the pharmacists in order to optimize each infusion line. 
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